Brodalumab met primary endpoints, deaths called ‘unrelated’

The investigational interleukin-17 inhibitor brodalumab met both primary endpoints in a phase III, double-blind, placebo-controlled trial of 661 patients with moderate to severe plaque psoriasis, investigators reported in the British Journal of Dermatology. By week 12, 83% of patients on 210 mg...
Source: Skin and Allergy News - Category: Dermatology Source Type: news